Jim Trevaskis
@jimmytrevaskis
Followers
940
Following
4K
Media
22
Statuses
767
Obesity researcher at Eli Lilly. Posts are own. 🇦🇺
Boston, MA
Joined July 2012
About a month to go to submit abstracts for the premier Obesity science meeting at Keystone, CO. Amazing speaker lineup, come along to connect and learn.
keystonesymposia.org
Join us at the Keystone Symposia on Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects, January 2026, in Keystone, with field leaders!
1
5
6
RT @MattWattUnimelb: See new job opportunity in our lab. •Collaborate with world-leading industry partner.•Join a dynamic team advancing me….
0
16
0
RT @DanielJDrucker: While the latest GLP-1 medicines are “new” exenatide was approved April 28 2005. Congratulations to John Eng, Amylin Ph….
0
27
0
RT @MattWattUnimelb: Incredibly proud of this work. We detail the evolution of liver-secreted and plasma proteins with MASLD progression, p….
cell.com
De Nardo et al. profile the plasma and liver-secreted proteome from obese individuals spanning the spectrum of MASLD. They identify biomarkers for MASH in persons with obesity and develop and...
0
10
0
RT @thewilliamslab: New DiabetesBio episode is out with fantastic authors @bruinjenny1 @LahariBasu_ and a special segment celebrating #Davi….
0
5
0
Only a few weeks away from exploring the various exciting aspects of obesity biology and therapeutics in lovely Crete! Come and join us to review the latest with an amazing speaker lineup!.
0
3
13
Proud dad moment!.
Another highlight from the Girls D2 State Swim Meet. Bella Trevaskis, 2nd from left finished 6th in the 100M Backstoke with a time of 1:02.16, a new school record. She also finished 4th in the 100M Free with a new school record of 54.59. AWESOME job Bella, GO SAILORS!
1
0
9
RT @srikosuri: It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendr….
0
6K
0
RT @AegeanConf: Reminder: Register and submit your abstract by Feb. 1, 2025 to the First Int'l Conference on #Obesity - #BiologicalDrivers….
0
4
0
It'll be a blast!.
Reminder: Register and submit your abstract by Feb. 1, 2025 to the First Int'l Conference on #Obesity - #BiologicalDrivers and #Therapeutic Approaches May 20-25 in #Crete, #Greece @KalimeraKriti Funds available for students/trainees! Apply!
0
0
3
RT @maddiehray: I’ve been getting a lot of requests for advice on moving from academia to industry. Here are my thoughts and the resources….
0
3
0
RT @ClaudioVillanu: Join us for the 2025 Obesity and Adipose Tissue #Keytstone Meeting in Banff. We are looking forward to stimulating pres….
0
5
0
RT @LoraHeisler: Join us for the exciting program at Aegean's First International Conference on Obesity - Biological Drivers and Therapeuti….
0
2
0
Support my Breakthrough T1D Walk representing Boston team Lilly!
breakthrought1d.org
The Breakthrough T1D Walk is a community celebration for those living with T1D and the research advancements we've all worked together to achieve. It's where dedicated families, friends and companies...
0
0
7
Ultimately the goal is to help patients. Good models allow for that. The approval of resmetirom is just the start - I believe in the future there will be multiple ways to treat NASH/MASH and fibrosis and improve outcomes for patients.
2
1
3
Huge thanks to: early collaborators and support at Amylin (Jon Roth, Dave Parkes), AstraZeneca/MedImmune (Chris Rhodes, Steph Oldham, Sarah Will), Gubra (@michael_feigh, Niels Vrang), Gilead (Rob Myers, Jamie Bates, Grant Budas, many others), and many other collaborators!!!.
1
0
1
This week, the LITMUS consortium published their unbiased analysis of NASH models relative to human context and the GAN model came out on top! The goal of a "standard" NASH model appears to be realized!.
nature.com
Nature Metabolism - The LITMUS consortium provides a resource of rodent MASLD models benchmarked against metabolic, histologic and transcriptomic features that are relevant for human MASLD. The...
1
2
8
Every agent that has been tested clinically has now been evaluated in the Gubra GAN model. Other models exist and have value in different ways - more fibrosis, faster disease onset etc. There are always needs for different models.
1
0
1